Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Zhejiang Hisun Pharmaceutical Co. Ltd. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and 1 distinct art unit. WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 1 pending office action. The portfolio's current activity is limited to 1 pending office action, representing a highly focused prosecution effort.
Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution process is currently centralized. This allows the company to focus its resources on the specific requirements of the single examiner and art unit involved in the biotechnology and pharmaceuticals sector. Practitioners can develop a highly targeted strategy for WHITE, DAWANNA SHAR-DAY without the need to coordinate across multiple points of contact. The outcome of this 1 pending office action will be the primary driver of the company's current patent standing. This streamlined structure minimizes administrative complexity and allows for a direct approach to the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571213 | SALT OF SELECTIVE FGFR4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571213 | SALT OF SELECTIVE FGFR4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | — | Pending | Dec 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Hisun Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Zhejiang Hisun Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
